Literature DB >> 2563577

Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.

J A Cohen1, D B Weiner, K F More, Y Kokai, W V Williams, H C Maguire, V A LiVolsi, M I Greene.   

Abstract

The neu gene (also called NGL, erbB-2, and HER-2) encodes a 185-190 kDa transmembrane glycoprotein, p185neu, which has tyrosine-specific kinase activity and is homologous to but distinct from the epidermal growth factor receptor. The normal expression of neu mRNA and protein has been demonstrated in epithelial tissues of adult animals. Also, activation of the neu oncogene has been implicated in a variety of human adenocarcinomas. In the present study, we examined the expression of the p185neu protein in normal and transformed digestive tract tissues and in a panel of digestive tract-derived cell lines. By immunohistochemistry, strong reactivity was observed in the mucosal epithelium of the stomach, small intestine, and colon of both rodents and humans. In the small intestine, there was prominent p185neu expression by mucosal epithelium of the villus, with little or no staining in the crypts. Prominent expression was observed in the liver parenchyma, the endocrine and exocrine portions of the pancreas, and in the salivary gland. Immunoreactive p185neu was also demonstrated in fetal human intestinal epithelium. Tissue sections of selected benign and malignant colonic neoplasms were also examined. Immunoreactivity was consistently greater in adenomatous polyps than in adjacent normal colonic epithelium or areas showing malignant degeneration. By radioimmunoprecipitation, there was decreased expression in cell lines derived from more anaplastic colonic tumors. The p185neu protein is expressed widely in normal and transformed epithelial tissues of the digestive tract of the adult rat and human. This finding suggests that p185neu, a putative growth factor receptor, may play a role in the regulation of normal growth and function or in the malignant transformation of these cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2563577

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

2.  HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.

Authors:  Dong Il Park; Mun Su Kang; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Won Kon Han; Hungdai Kim; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Int J Colorectal Dis       Date:  2006-09-01       Impact factor: 2.571

3.  Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution.

Authors:  H T Zhang; J E Kacharmina; K Miyashiro; M I Greene; J Eberwine
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 4.  Non-invasive, ultra-sensitive, high-throughput assays to quantify rare biomarkers in the blood.

Authors:  Jaclyn A Freudenberg; Kathryn Bembas; Mark I Greene; Hongtao Zhang
Journal:  Methods       Date:  2008-06-23       Impact factor: 3.608

5.  Structural and functional aspects of the multiplicity of Neu differentiation factors.

Authors:  D Wen; S V Suggs; D Karunagaran; N Liu; R L Cupples; Y Luo; A M Janssen; N Ben-Baruch; D B Trollinger; V L Jacobsen
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

6.  Prognostic significance of HER2/neu expression in gastric cancer.

Authors:  Julian Ananiev; Maya Gulubova; Irena Manolova; Georgi Tchernev
Journal:  Wien Klin Wochenschr       Date:  2011-07-11       Impact factor: 1.704

7.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

8.  Evaluation of serum HER2-ECD levels in patients with gastric cancer.

Authors:  Katsunobu Oyama; Sachio Fushida; Tomoya Tsukada; Jun Kinoshita; Toshifumi Watanabe; Masatoshi Shoji; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Isamu Makino; Keishi Nakamura; Hironori Hayashi; Masafumi Inokuchi; Hisatoshi Nakagawara; Tomoharu Miyashita; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Hirohisa Kitagawa; Takashi Fujimura; Ryousuke Tajiri; Akishi Ooi; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2014-02-21       Impact factor: 7.527

9.  Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.

Authors:  H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 10.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.